Trial Profile
Phase I /II trial to determine the feasibility of Tc-99m-tilmanocept to image high risk plaque by SPECT/CT in patients with and without aortic and high risk coronary atherosclerotic plaques and with and without HIV infection
Status:
Active, no longer recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 19 Aug 2021
Price :
$35
*
At a glance
- Drugs Tc 99m tilmanocept (Primary)
- Indications Atherosclerosis
- Focus Diagnostic use; First in man
- 11 Aug 2021 Status changed from recruiting to active, no longer recruiting as per Navidea Biopharmaceuticals media release
- 11 Mar 2020 According to a Navidea Biopharmaceuticals media release, the company is continuing the enrollment in this study.
- 11 Mar 2020 Status changed from active, no longer recruiting to recruiting, according to a Navidea Biopharmaceuticals media release.